Fig. 4
From: Immune characteristics and clinical significance of peripheral blood lymphocytes in breast cancer
PBL subsets are vulnerable to chemotherapeutic drugs. (A). Changes in PBL subsets in patients treated with the AC/EC-T/P regimen. (B). Changes in PBL subsets in patients treated with the PEC/TEC regimen. (C-D). Changes in (C) CD4 + T and (D) CD19 + CD32 + B in different BC molecular subtypes during adjuvant therapy chemotherapy cycles. Abbreviations: HR + HER2-, hormone receptor-positive/HER2-negative; HER2+, HER2-positive; TN, triple-negative; AC, adriamycin combined with cyclophosphamide; EC, epirubicin combined with cyclophosphamide; T, docetaxel; P, paclitaxel; H, herceptin; PEC, paclitaxel combined with epirubicin and cyclophosphamide; TEC, docetaxel combined with epirubicin and cyclophosphamide